Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C019199 + sintilimab
- Development stage
- Phase 2
- Lead developer
- Haixi New Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
C019199 + sintilimab is an investigational combination therapy being developed by Fujian Haixi Pharmaceuticals for the treatment of advanced solid tumors, including colorectal cancer, pancreatic cancer, gastric cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma. C019199 is a small molecule multi-targeted kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF-1R), discoidin domain receptor 1 (DDR1), and vascular endothelial growth factor receptor 2 (VEGFR2). Sintilimab is a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor. The combination aims to enhance anti-tumor immune responses by simultaneously inhibiting immunosuppressive pathways in the tumor microenvironment and promoting T-cell activation. It is currently in Phase 1 clinical development.
- Other names
- C019199 + PD-1 inhibitorC019199 combination with anti-PD-1C-019199 combination with anti-PD-1C 019199 combination with anti-PD-1
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)DDR1 (Discoidin domain receptor 1)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on C019199 + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C019199 + sintilimab.